Use of oncoscint scan to assess resectability of hepatic metastases from colorectal cancer

American Surgeon

Volumn 67, Issue 12, 2001, Pages 1200-1203

  Wendy, T S U ^a   Brachman, Michael ^a   O'Connell, Theodore X ^a  

^a KAISER PERMANENTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSTIC AGENT; DRUG DERIVATIVE; INDIUM; INDIUM 111IN SATUMOMAB PENDETIDE; INDIUM 111IN-SATUMOMAB PENDETIDE; MONOCLONAL ANTIBODY; OLIGOPEPTIDE; PENTETIC ACID;

ADULT; AGED; ARTICLE; COLORECTAL TUMOR; FEMALE; HUMAN; LIVER TUMOR; MALE; METASTASIS; PATHOLOGY; PROSPECTIVE STUDY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY;

AGED; ANTIBODIES, MONOCLONAL; COLORECTAL NEOPLASMS; FEMALE; HUMAN; INDIUM RADIOISOTOPES; LIVER NEOPLASMS; MALE; MIDDLE AGE; OLIGOPEPTIDES; PENTETIC ACID; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 0035651512     PISSN: 00031348     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. Greenfield LJ, Mulholland M, Oldham KT, et al. Surgery. 2nd Ed. Philadelphia: Lippincott-Raven, 1997, 1144-5.
2. Satumomab Pendetide. (OncoScint CR/OV package insert). Princeton, NJ: Cytogen Corporation, 1993.
3. 111In-CYT-103, in the management of colon cancer. Am Surg 1993;165:137-43.
4. Collier BD, Abdel-Nabi H, Doerr RJ, et al. Immunoscintigraphy performed with In-111-labeled CYT-103 in the management of colorectal cancer: Comparison with CT. Radiology 1992;185: 179-86.
5. Pinkas L, Robins PD, Forstrom LA, et al. Clinical experience with radiolabelled monoclonal antibodies in the detection of colorectal and ovarian carcinoma recurrence and review of literature. Nucl Med Commun 1999;20:689-96.
6. 111In-CYT-103 scanning in recurrent colorectal cancer: Does it affect standard management? Dis Colon Rectum 1996;39:514-9.
7. 111In-labelled anti-TAG72 monoclonal antibody. Nucl Med Commun 1999;20:123-30.